Literature DB >> 21479621

Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations.

Jochen Maul1, Martin Zeitz.   

Abstract

BACKGROUND: Ulcerative colitis (UC) is a complex disease in which the interaction of genetic, environmental and microbial factors drives chronic intestinal inflammation that finally leads to extensive tissue fibrosis. DISCUSSION: The present review discusses the current knowledge on genetic susceptibility, especially of the IL-12/IL-23 pathway, the pathophysiologic role of the involved cytokines (e.g. IL-13, IL-23, TGFβ1) and immune cells (e.g. T cells, epithelial cells, fibroblasts) in UC followed by an overview on actual therapeutic considerations. These future therapies will target selectively the involved cell types by blocking their activation and its downstream signalling, by inhibiting their migration to the inflamed site and by anti-cytokine strategies. This may avoid-when initiated in time-the perpetuation of the inflammatory mechanisms thus preventing fibrosis. With respect to animal models that have guided the most productive efforts for understanding human inflammatory bowel disease, these will be shortly discussed in the respective context.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479621     DOI: 10.1007/s00423-011-0789-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  96 in total

Review 1.  Developmental plasticity of Foxp3+ regulatory T cells.

Authors:  Shohei Hori
Journal:  Curr Opin Immunol       Date:  2010-09-09       Impact factor: 7.486

2.  RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

Authors:  Simon Travis; Lee Min Yap; Chris Hawkey; Bryan Warren; Mirella Lazarov; Tim Fong; R J Tesi
Journal:  Inflamm Bowel Dis       Date:  2005-08       Impact factor: 5.325

3.  The IL-23/IL-17 axis in inflammation.

Authors:  Yoichiro Iwakura; Harumichi Ishigame
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 4.  General principles and pharmacology of biologics in inflammatory bowel disease.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  Gastroenterol Clin North Am       Date:  2006-12       Impact factor: 3.806

5.  Can loss of immune tolerance cause IBD?

Authors:  Jochen Maul; Rainer Duchmann
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

6.  Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity.

Authors:  Nathalie Holmén; Anna Lundgren; Samuel Lundin; Ann-Marie Bergin; Anna Rudin; Henrik Sjövall; Lena Ohman
Journal:  Inflamm Bowel Dis       Date:  2006-06       Impact factor: 5.325

7.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

8.  Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.

Authors:  P Goyette; C Lefebvre; A Ng; S R Brant; J H Cho; R H Duerr; M S Silverberg; K D Taylor; A Latiano; G Aumais; C Deslandres; G Jobin; V Annese; M J Daly; R J Xavier; J D Rioux
Journal:  Mucosal Immunol       Date:  2008-01-16       Impact factor: 7.313

9.  Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy.

Authors:  Y Sumida; K Nakamura; K Kanayama; H Akiho; T Teshima; R Takayanagi
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

10.  Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells.

Authors:  Kenji Suzuki; Yusuke Kawauchi; Suresh S Palaniyandi; Punniyakoti T Veeraveedu; Masato Fujii; Satoshi Yamagiwa; Hiroyuki Yoneyama; Gi Dong Han; Hiroshi Kawachi; Yoshiaki Okada; Yoichi Ajioka; Kenichi Watanabe; Masamichi Hosono; Hitoshi Asakura; Yutaka Aoyagi; Shosaku Narumi
Journal:  Pathol Int       Date:  2007-07       Impact factor: 2.534

View more
  12 in total

Review 1.  Molecular oxygen sensing: implications for visceral surgery.

Authors:  Judit Kiss; Johanna Kirchberg; Martin Schneider
Journal:  Langenbecks Arch Surg       Date:  2012-03-07       Impact factor: 3.445

2.  Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice.

Authors:  Hai-Mei Zhao; Xiao-Ying Huang; Zhi-Qin Zuo; Qi-Hong Pan; Mei-Ying Ao; Feng Zhou; Hong-Ning Liu; Zhi-Yong Liu; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

3.  Chymase inhibitor TY-51469 in therapy of inflammatory bowel disease.

Authors:  Wei-Xin Liu; Ying Wang; Li-Xuan Sang; Shen Zhang; Ting Wang; Feng Zhou; Shou-Zhi Gu
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

4.  Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.

Authors:  Gunnar Brandhorst; Darinka Todorova Petrova; Sebastian Weigand; Christoph Eberle; Nicolas von Ahsen; Jessica Schmitz; Frank Christian Schultze; Dirk Raddatz; Michael Karaus; Michael Oellerich; Philip D Walson
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  Identification of diagnostic signatures in ulcerative colitis patients via bioinformatic analysis integrated with machine learning.

Authors:  Jiajie Lu; Zhiyuan Wang; Munila Maimaiti; Wenjia Hui; Adilai Abudourexiti; Feng Gao
Journal:  Hum Cell       Date:  2021-11-03       Impact factor: 4.174

Review 6.  The Function of Natural Polysaccharides in the Treatment of Ulcerative Colitis.

Authors:  Yafei Guo; Yang Li; Qiang Cao; Leilei Ye; Junmei Wang; Mei Guo
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

7.  Novel treatment options for ulcerative colitis.

Authors:  Byron P Vaughn; Alan C Moss
Journal:  Clin Investig (Lond)       Date:  2013-11

Review 8.  Changes of the cytokine profile in inflammatory bowel diseases.

Authors:  Györgyi Műzes; Béla Molnár; Zsolt Tulassay; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

9.  The potential protective role of caveolin-1 in intestinal inflammation in TNBS-induced murine colitis.

Authors:  Carolyn R Weiss; Qingdong Guan; Yanbing Ma; Gefei Qing; Charles N Bernstein; Richard J Warrington; Zhikang Peng
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

10.  Gastric epithelial expression of IL-12 cytokine family in Helicobacter pylori infection in human: is it head or tail of the coin?

Authors:  Fadi Al-Sammak; Thomas Kalinski; Sönke Weinert; Alexander Link; Thomas Wex; Peter Malfertheiner
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.